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Breast implant-associated anaplastic large cell lymphoma (BIA 
ALCL) is an uncommon disease that affects women after breast 
reconstruction or cosmetic enlargement. It usually presents as fluid 
collection or mass, which may occur after 1 year, but mostly around 
7 to 10 years after implant surgery. The cause for its development 
and risk factors are not known, but there is probably no influence of 
the material of the implant. We report two cases of women with BIA 
ALCL visualized by 18F-FDG Positron Emission Tomography-Com-
puted Tomography (PET-CT).
A 60-year-old woman underwent surgical reconstruction of 
both breasts in 2003 after mastectomy performed due to benign 
lesions that initially presented with high probability of malignancy. 
The patient underwent also combined hysterectomy and oopho-
rectomy in 2005. The implants were exchanged several times, 
due to various reasons, recently in August 2018. During the last 
procedure, in the right breast area a fluid collection was found and 
the pathomorphological analysis of the fluid disclosed BIA ALCL. 
The 18F-FDG PET-CT examination was performed and it showed 
metabolic activity around the implants, which corresponded to the 
lymphoma. There was also an increased uptake of 18F-FDG in the 
left axillary lymph node caused by BIA ALCL. On the right side, the 
lymph node was also enlarged but showed no increased uptake. 
Our second patient is a 34-year-old woman who underwent 
breast enlargement in 2013 by introducing implants. The ultrasound 
examination detected fluid collection in the left breast. Fluid aspira-
tion and pathomorphology confirmed BIA ALCL. 18F-FDG PET-CT 
examination confirmed metabolic activity at the lower pole of the 
left implant and infiltration of lymph nodes in left axillary.
Despite the rare occurrence of breast implant-associated 
lymphoma, patients should be carefully followed-up after sur-
gery. Ultrasound need to be performed in patients with clinical 
symptoms, like breast enlargement. After finding fluid collection 
the fine needle aspiration should be performed, or tissue biopsy 
if a mass is observed. The main treatment is surgical exploration 
with capsular biopsy, which provides very high survival rate. The 
preoperative 18F-FDG PET-CT should be recommended for detec-
tion of tumor spread and for accurate staging, as well as for the 
postoperative follow-up.
Figure 1. Maximal intensity projection (MIP) image (A) and fused axial PET/CT image of the breasts (B) showing a diffuse 18F-FDG uptake around 
both implants corresponding to BIA ALCL infiltrations in Patient 1
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Figure 2. Fused axial PET/CT image of the left breast in Patient 2 showing increased 18F-FDG accumulation around the nipple of the left breast (A) 
and in the left axillary lymph nodes (B)
